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1. INTRODUCTION 
1.1. Cleidocranial Dysplasia 
Cleidocranial Dysplasia syndrome is known by different names such as Marie 
Sainton syndrome, Mutational Dysostosis, Cleidocranial Dysostosis and 
Dysostosis Cleidocranialis (1). Cleidocranial Dysplasia was described for the first 
time in the 19th century by Gustav Scheuthauer, Pierre Marie and Paul Sainton(2, 3) 
who reported the two most striking manifestations, viz. the hypo- or aplastic 
clavicles and the abnormal, excessive number of teeth ranging up to 70 teeth in 
some cases (4). Since then, over 1000 cases from the whole world with a wide 
range of clinical manifestations have been documented in medical literature (5-7).  
In many medical references the abbreviation (CCD), which will be also used often 
in this research, has been used to describe this genetic disease. 
In 1908 the Swedish physician Hultkranz described this as ‘quatermoon’ 
physiognomy: ‘The nasion-alveolar line appears more upright than usual ( … ) if a 
protruding forehead and the strong prognathic mandible is added, the result is a 
concave facial profile, a quatermoon physiognomy’ (8). 
Cleidocranial Dysplasia is notable for aplasia or hypoplasia of the clavicles, 
characteristic craniofacial malformations, and the presence of numerous 
supernumerary and unerupted or impacted teeth (9). Other clinical hallmarks of 
CCD include delayed or failure in the closure of cranial fontanels and sutures, in 
addition to other skeletal anomalies.  Thus, CCD is not limited to the craniofacial 
region; it is defined by many medical references as a generalized dysplasia and 
skeletal disorder of the entire skeletal system (10, 11). 
It is considered to be a rare genetic defect affecting mainly the membranous bone 
formation, with an incidence estimated at 1: 200,000 live births (5) and a 
prevalence of 1: 1,000,000 (12), affecting in most cases the skull and the clavicles. 
However, the prevalence of affecting other parts of the skeleton is still high. 
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1.1.1. Etiology and Pathogenesis  
Cleidocranial Dysplasia is transmitted by an autosomal-dominant mode of 
inheritance with high penetrance and a different degree of expressivity affecting 
both skeletal and dental systems (13, 14). A recessive form of this syndrome has 
been reported in two families. About one third of the cases show different and new 
mutations. The frequency of Cleidocranial Dysplasia is almost the same among 
males and females; and there is also no racial predilection.  
Studies involving large population groups in South Africa have localized the origin 
of this disorder to the short arm of chromosome 6p21 and confirmed that the 
transcription factor (Runx2) is the causative factor of this genetic disorder (15, 16).  
Most patients with this disorder are of normal intelligence (9), and until now there 
are no studies supporting any relation between CCD and a low IQ level. Many 
patients treated in the orthodontic clinic of Regensburg University Hospital, 
showed good intelligence and, in some cases managerial, work positions.  
Intramembranous and endochondral bones in the skull are primary affected, 
resulting in a sagittally diminished cranial base, transverse enlargement of the 
calvarium, and delayed closure of the fontanels and sutures (17, 18). Late closure of 
fontanels is also considered as a common pathological feature of other 
syndromes, such as Basal cell nevus syndrome and Crouzon’s syndrome 
(Craniofacial syndrome), but together with other characteristic features, 
Cleidocranial Dysplasia can be easily differentially diagnosed (5, 9).  
The biparietal and frontal bossing and the extension of the cranial vault result from 
the hydrocephalic pressure exerted on unossified regions of the skull, especially 
the fontanel areas. The deficiency or complete absence of the clavicles is 
responsible for the characteristic long appearance of the neck and the narrow 
shoulders. In general, the special facial appearance of CCD is a result of the 
underdeveloped and abnormal middle third of the face combined with the 
abnormalities in the dental alveolar complex (9, 17). 
Many studies have supported the idea that delayed or failed eruption of the teeth 
is associated with a lack of cellular cementum. This failure of cementum formation 
is thought to be a direct result of the mechanical resistance to eruption due to 
dense alveolar bone overlying the unerupted teeth. On other hand, it has been 
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hypothesized, that the formation of supernumerary teeth might be due to 
incomplete or severely delayed resorption of the dental lamina which is reactivated 
at the time of crown completion of the normal permanent dentition (9). However, 
until now there is no definitive explanation for this phenomenon.  
1.1.2. Clinical Manifestations 
The clinical appearance of Cleidocranial Dysplasia includes very characteristic and 
distinct features that make this syndrome very pathognomonic (Fig.1). In general, 
the patients show a mildly to moderately shortened stature, with the neck 
appearing elongated and narrow and the shoulders markedly drooped or at least 
oblique at 45
o
, which results from absent or malformed clavicles (9). About 10% of 
CCD patients have been 
recorded to show complete 
failure in the formation of the 
clavicles. 
Hypermobility    of    the shoulders, 
which is very characteristic of 
CCD patients, is a result of 
complete or partial absence of 
clavicular calcification, with 
associated muscular defects. 
This enables the patients to 
show variable levels of 
approximation of the shoulders 
in the anterior plane (17, 19). 
The head is large and brachycephalic with a persistent metopic (frontal) suture (20). 
Most patients show pronounced frontal, parietal, and occipital bossing. The facial 
bones and paranasal sinuses are hypoplastic or aplastic, giving the face a small 
and short appearance. The nose is also affected. CCD patients show a broad 
based nose, with a depressed nasal bridge. Ocular hypertelorism had been 
recorded for this syndrome (21) (Fig.1).  
In general, the entire skeleton can be affected, with defects of the pelvis, long 
bones, and long fingers. Hemivertebrae and posterior wedging of the thoracic 
Fig.1. Extra-oral photos of 19 years old patient with CCD 
syndrome, who is being treated in the Orthodontic and 
Maxillofacial Surgery clinic in Regensburg University 
Hospital. (A) Shows somehow large head with broad 
based nose and poorly developed middle face. (B)
Shows profile hallmarks of CCD: 1. prominent forehead, 
2. Depressed nasal bridge, 3. Maxillary hypoplasia, 4.
Mandibular progenie with prominent chin. Regensburg 
University Hospital, Orthodontic Clinic Archive 
A 
1 
2 
3 
4 
B 
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vertebrae may contribute to the development of kyphoscoliosis and pulmonary 
complications (17) (Fig.2).  
The clinical manifestations associated with the CCD syndrome can be classified 
based on the affected region as follows: (10, 11, 22, 23) 
 
Region Common associated symptoms 
Head 1. A large brachycephalic head. 
2. A broad forehead with frontal, parietal or occipital bossing. 
3. Delayed or failed closure of the fontanels and sutures. 
4. Poorly developed mid-frontal area showing a frontal groove. 
5. Soft skull in infancy. 
Face 1. A depressed nasal bridge. 
2. Hypertelorism with possible exophthalmos. 
3. A small, flattened facial appearance (mid-face hypoplasia) 
with prognathic mandible (true or pseudo-progenia). 
4. Vertical maxillary deficiency. 
Shoulders 
and thorax 
1. Ability to approximate the shoulders in the anterior plane. 
2. Dimpling of the skin due to mild hypoplasia of the clavicles. 
3. Sloping, almost absent shoulders secondary to severe 
hypoplasia or complete absence of the clavicles. 
4. Narrow thorax which may lead to respiratory distress during 
early infancy. 
Spine 1. Scoliosis, 2.  Kyphosis. 
Hands 1. Brachydactyly. 
2. Short distal phalanges. 
3. Tapering fingers. 
4. Nail dysplasia or hypoplasia. 
5. Short, broad thumbs. 
6. Clinodactyly of the 5th fingers. 
Other 
abnorma-
lities 
1. Hearing loss. 
2. Abnormal gait. 
3. Joint hypermobility. 
4. Muscular hypotonia. 
 
TABLE 1. Summary of all possible affected regions in CCD with the common associated symptoms 
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1.1.3. Oral and Dental Manifestations 
The underdeveloped (hypoplastic) maxilla leads to a relatively prognathic 
appearance of the mandible. However, some patients may exhibit different 
degrees of real or true mandibular prognathism, due to a considerable increase of 
lower jaw length in relation to a short cranial base. In most cases, the palate is 
narrow and highly arched, and there is an increased incidence of submucosal 
median clefts (Fig.3). 
Fig.2. Schematic illustration of the major and minor affected regions in patients with cleidocranial 
dysplasia (24). Note that most of the skeletal system may be affected with different defects; however, 
the severity of these defects is still highly variable. The areas with dark shading represent the sites 
most frequently affected with cleidocranial dysplasia mutational symptoms of high severity. Regions 
like the clavicles, cranial sutures, dentofacial complex and pelvis, with black shading, in most cases 
show a severe degree of defects and deformations. 
On other hand, areas with light shading like the thoracic, vertebral column and the carpal and tarsal 
may show mild symptoms or, in some cases, may not show any form of deformations or functional 
defects. 
Delayed closure of sutures and 
fontanels 
Deep ear insertions 
Wormian bones 
Hypoplastic or aplastic clavicles 
Thoracic deformities 
Scoliosis 
Narrow pelvis 
Vertebral anomalies 
Genu valgus 
Carpal and tarsal malformations, 
onychodystrophy 
Disturbed ossification of 
pubic and ischiadic bone, 
coxa vara, coxa valga 
Delayed symphysis 
closure 
Hypoplastic midface, 
shortened skull base, basilar 
kyphosis 
Scapular malformations 
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Complete or partial clefts of the palate, which may involve both the hard and soft 
tissues, have also been diagnosed in many cases. In the lower jaw, delayed 
closure of the mandibular symphysis was reported by Scully and Cawson (20). 
However, complete nonunion of the symphysis of the mandible was also found in 
some CCD patients (9). 
The development, maturation, and 
eruption of the primary teeth are mostly 
normal. However, an extreme delay in the 
process of normal and expected root 
resorption of primary teeth occurs, which 
results in prolonged retention and late 
exfoliation of deciduous dentition. The 
physiologic eruption of the permanent 
dentition is severely delayed, and in many 
patients more than half of the teeth fail to 
erupt (19). Adult individuals with Cleidocranial Dysplasia who show a mixed 
dentition (both primary and permanent teeth) in their oral cavity are a very 
common observation 
Unerupted or retained supernumerary teeth are often present in all regions of both 
jaws, and mostly look like the premolars (9). As many as 63 unerupted 
supernumerary teeth were documented in one patient (25). These teeth develop by 
the time of completion of normal crown formation in the permanent dentition, just 
lingually and occlusally to the normal unerupted crown. In general, one 
supernumerary tooth per normal tooth is noted on average. 
Severe malocclusion and crowding is often a characteristic dental finding in 
patients with this congenital syndrome. Many factors contribute to the 
malocclusion including over-retention of the deciduous (primary) teeth, failure of 
eruption of the permanent teeth, presence of numerous supernumerary teeth and 
maxillary hypoplasia. In most cases, this type of malocclusion poses a real 
challenge in orthodontic practice (9). The incidence of twisted roots, malformed 
crowns and dentigerous cysts is also significantly elevated in CCD patients (20). 
Fig.3. Intra-oral Photo of the same patient in 
Figure [1], same age also, demonstrating a 
submucosal median palatinal cleft. Regensburg 
University Hospital, Orthodontic Clinic Archive 
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Fig.4. OPG of 15,4 years old patient, who was admitted in the orthodontic clinic in Regensburg 
University Hospital, due to delayed eruption of the permanent teeth, multiple retained teeth and 
presence of supernumerary teeth. January 2001. Note the supernumerary teeth marked with white 
arrows and the severely rotated and malpositioned permanent teeth marked with red arrows. 
Regensburg University Hospital, Orthodontic Clinic Archive 
1.1.4. Radiographic Findings  
Radiography is considered a very important diagnostic tool to confirm the 
diagnosis of Cleidocranial Dysplasia. It reveals the various abnormalities of the 
craniofacial region, dentition, clavicles, and pelvis. Radiographs of the skull 
classically exhibit patent fontanels and wormian bones, broad and anomalous 
cranial sutures, in addition to underdeveloped paranasal sinuses. The clavicles 
may be hypoplastic, unilaterally or bilaterally appearing as small fragments 
attached to the sternum process, or may be completely absent (aplastic). The 
mandible and maxilla contain many unerupted and supernumerary teeth which are 
often malpositioned and distributed in different areas of the jaws (24). Such dental 
findings can be easy distinguished by orthopantomogram (OPG) (Fig.4).  
 
L 
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1.1.5. Treatment 
There is no definite treatment protocol for patients with Cleidocranial Dysplasia. 
Genetic counseling is the first step in decision making and treatment planning. 
Early diagnosis of the syndrome is very critical for correct timing of treatment 
onset, especially regarding the various dental and maxillofacial anomalies (26, 27). 
Ideally, therefore, the diagnosis should be made before the age of 9 (17).  
The present mode of treatment of the dental anomalies combines both early 
surgical procedures and orthodontic therapy, in addition to some protective 
procedures. In the early childhood, wearing a protective headgear is highly 
recommended; especially while the fontanels remain patent.  
As a first step in the combined 
dental treatment, all 
supernumerary teeth and over-
retained primary teeth should 
be surgically extracted, when 
the root formation of 
succedaneous teeth exceeds 
50%. This is followed by 
surgical exposure of unerupted 
teeth. Many researchers 
reported that early surgical 
exposure of unerupted teeth 
may result in a stimulation of 
cementum formation and 
spontaneous eruption of the dentition with normal physiologic root formation. 
However, in most cases, the permanent teeth fail to erupt physiologically, which 
requires orthodontic intervention to move the teeth to the level of occlusion using 
special appliances with controlled orthodontic forces.  
Due to complete failure of tooth eruption, even when orthodontically assisted, 
orthognathic surgery, postsurgical orthodontic therapy, and prosthetics are 
anticipated in many cases with dentofacial disharmony (9) (Fig.5). 
 
Fig.5. Extra-oral photos of the previously demonstrated 
patient (23 years old) with CCD syndrome. The photos 
show considerable improvement in his profile and facial 
esthetics after he had been operated in the Maxillofacial 
Surgery clinic in Regensburg University Hospital. Note 
the surgical reposition of both jaws. Regensburg University 
Hospital, Orthodontic Clinic Archive 
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1.2. RUNX2 
The Runx2 gene (osteoblast-specific transcription factor) (28), also known as Core-
binding factor α1 (CBFα1), PEBP2A1, and AML3, is considered to be the master 
transcription factor of bone and plays a major role in all phases of bone formation. 
It is also responsible for the initial turnover of pluripotent mesenchymal cells into 
osteoblasts (29).In addition, its presence controls the proliferation, differentiation, 
and maintenance processes of these cells (16, 30, 31). Its involvement in the 
development of calcified tooth tissue, and its influence on proliferation of the dental 
lamina, makes Runx2 a very important factor also in the later stages of tooth 
formation (31-33). Furthermore, Runx2 regulates the alveolar remodeling process, 
which is essential for tooth eruption and may play a role in the maintenance of the 
periodontal ligament integrity (29). 
Mutations or deletions of Runx2 have been identified as the responsible and 
causative factor of the Cleidocranial Dysplasia syndrome (22). This has been 
proved by a large number of in vitro experiments and finally confirmed by the 
complete absence of ossification in Runx2-knockout mice (30, 34-36). 
This gene belongs to the runt domain (RUNX) family of genes, which consists of 
three members: Runx1, Runx2 and Runx3.These genes have been identified and 
localized on human chromosomes 21q22.12, 6p21 (22) and 1p36.1 respectively (36-
40). 
1.2.1. Runx2 Structure and Expression 
The Runx2 gene spans approximately 220 kb of the 6p21 human chromosome, 
contains eight exons (16, 41, 42) and shares significant structural similarity with other 
Runx-family members. The runt domain has an s-type immunoglobulin structure 
and mediates binding to the core DNA sequence (5’-PuACCPuCA-3’) and its 
complement (5’-TGPyGGTPy-3’) (39, 40).  
The expression of the Runx2 gene is initiated by two promoters separated by exon 
1 and a large intron. The distal and the proximal promoter (P1 and P2, 
respectively) generate two major transcripts (proteins) isoforms, namely type II 
(starting with the sequence MASNS) and type I (starting with the sequence 
MRIPV), respectively (Fig.6). It is well-known that both protein isoforms are 
expressed in osteoblasts and in terminal hypertrophic chondrocytes, however, 
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type I isoform expression has also been detected in many other non-osseous 
tissues (43). 
Runx2 binds to DNA interacting with the small protein core binding factor (CBF), 
which is a common component of all Runx proteins. In normal instances, CBF 
does not bind to DNA itself; however, it has the ability to enhance the DNA-binding 
capacity of Runx proteins and to increase their half-life stabilizing them against 
proteolytic degradation by the ubiquitin–proteasome system (45).  
The transcriptional activity of Runx2 is mediated by multiple activation and 
repression domains. Runx2 contains three activation domains: AD1, AD2 & AD3. 
The domain (AD3), which is the principal activation domain, is a 
proline/serine/threonine (PST)-rich region positioned near the C-terminal part of 
Runx2. However, both domains AD1 and AD2 are located at the N-terminal. AD2 
is located in a region adjacent to the N-terminus of the protein which is rich in 
glutamines and alanines (QA domain). The latter two domains have the ability to 
potentiate the maximal transcriptional capacity of Runx2. The last five C-terminal 
amino acids, known as VWRPY motif, are a common characteristic of all Runx 
proteins and show a repression activity (Fig.6) (46). 
Like any other members of the Runx family, Runx2 is able to repress transcription 
independently of TLE/Groucho proteins, through interaction with other co-
repressors such as histone deacetylases (46). The localization of Runx2 is 
regulated by a 9-amino acid sequence positioned at the junction of the runt and 
Fig.6. Schematic illustration of the Runx2 structure. The Runx2 gene comprises 8 exons and its 
transcription is controlled by two promoters, P1 and P2, which give rise to transcripts/protein 
isoforms, type II and type I, respectively. The Runx2 proteins contain multiple functional domains: 
AD1-3, transactivation domains; QA, glutamine/alanine rich domain; RUNT, runt homology domain; 
NLS, nuclear localization signal; PST, proline/serine/threonine rich domain; NMTS, nuclear matrix 
targeting signal; RD, repression domain; VWRPY, conserved repression “domain” of runt proteins 
(44) 
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PST domains. This nuclear localization signal (NLS) is rich in basic residues and 
can be seen in other runt-related proteins (Fig.6) (47). Besides the nuclear 
localization of Runx2, it exhibits a subnuclear topography as well, which is 
required for maximal transcriptional activity. A 31-amino acid Nuclear Matrix 
Targeting Signal (NMTS) directs Runx2 to subnuclear foci and reinforces its 
integration with the nuclear matrix (48). 
1.2.2. Biological Functions of Runx2 
Osteoblasts are the key bone cells responsible for building and repairing bone. It is 
well-known that Runx2 has a critical role in osteoblast differentiation, function and, 
consequently, in bone biology. Runx2 determines, at the early stage of 
embryogenesis, the osteoblast lineage from multipotent mesenchymal stem cells, 
but inhibits this process at the late stage (31).  
Runx2 binds to OSE2 sites which are found in the promoter region of all major 
osteoblast related genes, thus controlling their expression. Such ectopic 
expression of Runx2 in mesenchymal cell lines leads to up-regulation of these 
osteoblast-related genes like osteocalcin, alkaline phosphatase, collagenase-3, 
bone sialoprotein and collagen type I (30). Several studies have shown that in 
homozygous mice with a mutated Runx2 gene, there is a complete lack of 
ossification and both intramembranous and endochondral ossification are totally 
blocked due to the maturational arrest of osteoblasts (35). As a result, Runx2-
knockout mice display an absence of osteoblasts and bone formation, while the 
heterozygous mice show specific skeletal abnormalities that are very similar to and 
characteristic of the human heritable skeletal disorder, Cleidocranial Dysplasia 
(CCD) (36) (Fig.7).  
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Runx2 is also expressed in hypertrophic chondrocytes and is involved in their 
differentiation process (50, 51). Despite the crucial importance of Runx2 proteins for 
bone formation and repair, tissue-specific over-expression of the same proteins in 
transgenic mice leads to osteopenia, decreased bone mineral density and multiple 
fractures and bony defects (52). These findings have demonstrated the importance 
of regulation of Runx2 expression and its activity in bone pathology and biology.  
Regarding the different cellular functions of the two major Runx2 isoforms (type I 
and type II), a number of studies suggest that both isoforms are engaged in the 
stimulatory action of osteoblast differentiation. However, they support separate 
functions at different stages of osteoblast differentiation and bone formation. The 
two affected processes of bone formation are the endochondral and 
intramembranous stages (43). It has been proved that the type I isoform is mainly 
involved in intramembranous bone formation, whilst the type II isoform has an 
exclusive role in endochondral bone formation (53). Type I isoform is widely 
expressed in osteoprogenitor cells and in active osteoblasts during 
Intramembranous bone formation, whereas type II isoform expression is only seen 
in cells lining mineralized bones (43, 53). 
Fig.7. Runx2 homozygous mice display defects of the cranium and clavicles during post-natal 
growth. The skeletal phenotypes were determined using alizarin red/alcian blue (AR/AB) stains for 
bone and cartilages respectively. (A) The Hypoplastic clavicles. (B) The skull shows cranial defects 
including a wide suture, a decreased basis sphenoid bone (arrow) and non-osseous tissue present 
in the junction of the posterior frontal suture and the coronal suture (49) 
 A B 
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Runx2 is responsible for mediating and coordinating multiple signaling pathways 
that affect osteoblast function. A variety of chemical and physical stimuli including 
those initiated by ECM, osteogenic growth factors (e.g. bone morphogenetic 
proteins (BMPs) and fibroblast growth factor-2 (FGF-2)), hormones (e.g. 
parathyroid hormone and growth hormone) and mechanical loading 
(strain/stretching) can modulate the phosphorylation/activation status of Runx2. 
Moreover, they can support its interaction with other proteins, such as the 
transcriptional activators (e.g. activator protein-1 (AP-1) and SMADs), 
transcriptional repressors and co-repressors, histone acetylases and deacetylases 
(54-56). 
Fig.8. This diagram demonstrates the regulating effect of Runx2 on osteoblasts and odontoblasts 
differentiation. Runx2 promotes the differentiation of pluripotent mesenchymal cells into 
osteoblasts and odontoblasts lineage, increases the number of immature cells, but inhibits their 
maturation. It has been noticed that preosteoblasts and preodontoblasts express Runx2 
abundantly at the early stages of cells differentiation. Later, however, it will be down-regulated by 
immature osteoblasts and odontoblasts. In mature cells Runx2 has an inhibiting effect of the 
terminal differentiation, and therefore, is not expressed anymore by these cells (57) 
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1.2.3. Runx2 and Bone Tissue 
Bone tissue mainly consists of hydroxyapatite crystals beside various types of 
other extracellular matrix (ECM) proteins, including type I collagen, osteocalcin, 
osteopontin, osteonectin, bone sialoprotein (BSP), and proteoglycans (58, 59). These 
bone matrix proteins are secreted and deposited via polarized mature osteoblasts 
aligned on the bone surface (60). Many studies were focused on the precise role of 
matrix proteins in the formation of bone. Until now, however, their actions still are 
not fully explained (61, 62). Osteoblasts also regulate the formation of hydroxyapatite 
crystals.  
The experiments of Runx2-null mice clearly demonstrated that this transcription 
factor is critical for osteoblast differentiation, as these mice showed no bone 
tissue, osteoblasts or osteoclasts, despite normal cartilaginous skeletal patterning. 
Chondrocyte maturation, however, is disturbed in consequence (35, 36). 
Runx2 expression is also very critical for mature osteoblasts. Mature mice, in 
which active Runx2 levels have been reduced, exhibited a decreased expression 
of the genes encoding the main bone matrix proteins, such as osteocalcin, 
osteopontin, BSP and collagen type I (31). These genes are regulated through the 
Runx2-binding sites in the proximal promoter segments of the mentioned genes 
(63). Thus, it has been proved that Runx2 is essential for normal bone formation, 
while insufficient levels regardless of their reason result in disturbed bone 
formation. 
Over-production of Runx2 proteins will also affect bone formation. Osteoblasts 
taken from non-syndromic synostosed sutures in children showed an increase in 
Runx2 expression, which explains the enhanced proliferation and bone-forming 
ability of these cells (64). Many researches demonstrated that Runx2 expression 
decreases with age which could be a possible explanation for impaired osteoblast 
function and reduced bone formation with aging (65).  
Runx2 expression is affected by a diversity of signaling pathways. The Runx2 
gene, in fact, plays a central role in coordinating multiple signaling pathways 
affecting osteoblast differentiation (66) (Fig.8). 
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1.2.4. RUNX2 Domains 
Runx2 binds to the core binding factor site, which is also known as the osteoblast-
specific cis-acting element 2 (OSE2) (67). The RHD is responsible for the DNA-
binding properties of Runx2.  
One major repression domain and three transactivation domains have been 
recognized in the Runx2 protein (47). We will start here explaining the various 
activation domains of Runx2 gene.  
The first transactivation domain is located in the N-terminal 19 amino acids of the 
protein, while the second is located in the glutamine/alanine (Q/A) domain. The 
transactivation of Q/A domain depends on a stretch of 29 glutamine residues. 
Interestingly, deletion of the alanine stretch does not affect the transactivation 
process; however, expansion has a repressive effect (22). In addition, this 
expansion may also play an essential role in nuclear localization (68). The third 
transactivation domain is present in the N-terminal portion of the 
proline/serine/threonine (PST)-rich domain. A mutation in this region has been 
shown to cause a failure to interact with SMADs, which may accordingly reduce 
the response of osteoblasts to the Transforming growth factor-b/Bone 
morphogenetic protein (TGF-b/BMP) signaling pathway (69). This region has also 
been shown to interact with the co-activator molecule (p300), affecting in result the 
expression of the osteocalcin gene (70). This action is independent of the acetyl-
transferase activity of p300, which also protects Runx2 from degradation by SMAD 
ubiquitin regulatory factor (SMURF)-mediated ubiquitination and also increases 
the transactivation potential of Runx2 (71).  
The C-terminal part of the PST domain is a repression domain (47, 72). The terminal 
five amino acids (the VWRPY motif) are very highly conserved and have the ability 
to bind to the co-repressor proteins of the transducin-like enhancer of split (TLE) or 
Groucho related genes (Grg) family (73). 
The down-regulation and repressing of TLE/Grg expression during osteoblast 
differentiation is considered a very essential mechanism for relief of Runx2 
repression during cell differentiation (74). 
Other parts of the Runx2 gene have been shown to react with other co-repressors, 
such as histone deacetylases (HDAC) (72), SIN3 (75), and yes-associated proteins 
(YAP) (76). After the transcription process, Runx2 will be imported to the nucleus 
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where it binds to specific regions of the nuclear matrix to effect transcriptional 
control (77), co-localizing with co-activators (e.g. SMADs (78) and RNA polymerases) 
at nuclear sites that support RNA synthesis (48).  
This function is affected by the nuclear matrix targeting signal (NMTS) region, 
which is a 38 amino acid segment situated between the RHD and PST domains 
(79). Studies have demonstrated that point mutations in the NMTS region directly 
affect the intranuclear localization of Runx2 which in turn affects its interaction with 
target genes involved in osteolytic activity (69, 80). The interaction of transcription 
factors with cellular signal transducers at particular points in the nuclear matrix 
may somehow explain the tissue-specific action of the Runx2 proteins and of 
transcription factors in general. 
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1.3. Strontium Ranelate 
In the last decade, several effective medical compounds have been introduced for 
treatment of osteoporosis. Vertebral and non-vertebral fractures were decreased 
by 30-65 % through treatment with anti-catabolic agents (which decrease the bone 
resorption rate) or anabolic agents (which increase the bone formation and 
mineralization rate) (81).  
1.3.1. Chemical Structure and Characteristics 
Strontium ranelate (SR) is a new chemical compound composed of two atoms of 
stable Strontium (Sr2+) and an organic acid (ranelic acid), which acts as a carrier 
(82, 83) (Fig.9).  
 
 
 
 
 
 
 
 
 
  
 
The mineral Strontianite is named after the Scottish village of Strontian which has 
been discovered in the lead mines there in 1787 (84). However, Strontium itself was 
discovered in 1798 by Thomas Charles Hope (85). It occupies a middle position 
between Calcium (Ca2+) and Barium (Ba) in the periodic table with atomic number 
38. Many studies have demonstrated the high atomic and ionic similarity between 
Calcium and Strontium (86).  
Strontium ranelate represents a new generation of oral anti-osteoporotic agents 
electively concentrated in positions of active bone formation and exerting both 
anti-catabolic and anabolic effects on bone cells (81). It was first used in the 
treatment of osteoporosis in the 1950s.  Strontium itself is not found in its free 
Fig.9. Strontium Ranelate, systematic (IUPAC) name: distrontium 5-[bis (2-oxido-2-oxoethyl) 
amino]-4-cyano-3-(2-oxido-2 oxoethyl) thiophene-2-carboxylate; chemical formula: C12H6N2O8SSr2 . 
The figure demonstrates the chemical structure of SR. The molecule of the organic ranelic acid is 
marked with red color, while both Strontium atoms were marked with black color.  
(84) 
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form, because of its high tendency to oxidate spontaneously even at room 
temperature turning to yellow color as a result of oxide formation. It is found in 
different concentrations in some natural sources such as vegetables and cereals 
(87). 
1.3.2. Medical and Biological Functions 
Strontium ranelate has the ability to reduce the risk of vertebral (88), non-vertebral 
and hip (89, 90) fractures in postmenopausal osteoporotic women (PMOP).  
SR increases bone formation and decreases bone resorption rates (90-97) which 
results in the prevention of bone loss and a general increase in bone mass and 
strength (83, 95, 98-101). This unique effect on the bone remodeling process makes 
Strontium ranelate the only anti-osteoporotic agent, which can rebalance the bone 
turnover process in favor of bone formation. It is therefore referred to as a "dual 
action bone agent" (DABA) (88). 
Many animals and in-vitro experiments (94) as well as measurements of 
biochemical markers of bone turnover in clinical trials on osteoporotic women (88) 
have demonstrated the promoting effect of Strontium ranelate on bone formation 
and depressing effect on the bone resorption process. Several experiments on 
ovariectomized (OVX) or immobilized osteopenia rats have confirmed that 
Strontium ranelate could totally prevent bone loss and resorption in the 
experimented animals (102-104).  
At the macroscopic level, recent studies reported that the increase in bone 
strength induced by Strontium ranelate in rats may be explained by improvement 
of the micro architecture as well as the intrinsic bone tissue quality measured by 
hardness and dissipated energy upon nano-indentation (99). The anabolic effect of 
strontium on bone metabolism have been also observed and reported in intact 
animals, such as mice (105), rats (98) and monkeys (105). 
Microscopically, Strontium has been shown to enhance and significantly promote 
the replication and the functional activities on bone surfaces. It is able to increase 
osteoblast replication, osteoblast differentiation, collagen type I synthesis and 
bone matrix synthesis and mineralization (92, 93, 96, 106).  
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On other hand, it inhibits the formation of osteoclasts and decreases the number 
of differentiated osteoclasts (92). Further investigations have reported an induction 
of apoptosis of mature osteoclasts (107-109). 
Moreover, analysis of bone markers detected that strontium ranelate reduces the 
urinary excretion of the bone resorption marker, type I collagen N-telopeptide, 
while it increases the levels of a serum marker of osteoblast differentiation and 
bone-specific alkaline phosphatase (110).  
Thus, the functions of Sr2+ can be summarized as follow: 
1. Reducing the incidence of vertebral, non-vertebral and hip bone fractures in 
PMOP. 
2. Promoting the bone remodeling process by increasing bone formation and 
decreasing bone resorption rates. 
3. Increasing bone strength and mass and improving bone architecture quality. 
4. Supporting the differentiation of MSCs into osteoblasts. 
5. Accelerating the maturation of osteoblasts. 
6. Increasing the synthesis of collagen type I and mineralization of bone matrix.  
7. Suppressing the formation and function of osteoclasts and promoting 
osteoclasts apoptosis. 
8. Controlling urinary excretion of the different bone markers in favor of 
decreasing bone resorption and increasing osteoblast differentiation and bone 
formation and deposition.    
1.3.3. Signaling Pathways 
Despite the huge number of studies and experiments conducted on Strontium 
ranelate and its mode of action, the precise molecular mechanisms involved are 
still elusive and unclear. However, there is strong evidence that the calcium-
sensing receptor (CaSR), which is a critical factor for bone development and 
turnover processes (111), is involved in the actions of Strontium ranelate (112-118). 
Because of the atomic and ionic similarity between Strontium (Sr2+) and Calcium 
(Ca2+), it has been hypothesized that Sr2+ may also act as an agonist of the 
extracellular CaSr expressed in all stages of osteoblasts differentiation and 
maturation (119, 120). 
INTRODUCTION   24 
 
 
Studies have shown that within physiologic Ca2+ concentrations, Strontium 
ranelate can induce further CaSR activation comparing to Ca2+. It has also been 
demonstrated that Strontium ranelate is less potent than Ca2+ in stimulating 
inositol phosphate accumulation, but almost equals Ca2+ in stimulating extra-
cellular signal-regulated kinase (ERK) phosphorylation and a non-selective cation 
channel which strongly suggest that both Ca2+ and Strontium ranelate have 
differential cellular effects (121). Moreover, the retardation in activation of mitogen-
activated protein (MAP) kinase and protein kinase C (PKC) pathways mediated by 
Strontium ranelate compares to activation mediated by CaCl2. Thus, the existence 
of molecular mechanisms at least partially separate from Ca2+ (122) is supported. 
One of the recent studies on rat primary osteoblasts confirmed that the 
proliferation and the expression of genes involved in osteoblast proliferation and 
differentiation, such as (c-Fos) and (Egr-1), was stimulated by Strontium ranelate. 
Conversely, these effects were suppressed by over-expressing the dominant 
negative CaSR which suggests that Sr2+ action was mediated by Calcium-sensing 
receptor mechanisms (121). Similar results were obtained in other studies, where 
the Strontium ranelate-induced stimulation of replication was completely inhibited 
by transfection of a dominant negative CaSr (121,123). 
As a conclusion, Strontium ranelate can be considered as a full CaSr agonist in 
primary osteoblasts and its proliferative effect on these cells can be, at least 
partially, explained by a CaSr-dependent mechanism (82). 
1.3.4. Differentiation of Mesenchymal Stem Cells into Osteoblasts 
Strontium Ranelate promotes the differentiation from early progenitor cells to 
mature osteoblasts by increasing the expression of osteoblastic markers such as 
Runt-related transcription factor 2 (Runx 2), alkaline phosphatase (ALP), bone 
sialoprotein (BSP) and osteocalcin (OC) through Calcium-sensing receptor 
mechanisms (92). In vitro, bone marrow stromal cells exposed to a differentiating 
medium for 21 days and treated with Strontium ranelate showed an increase in the 
transcriptional activity and phosphorylation level of Runx2 gene, but not of 
osteocalcin (96). On other hand, Sr2+ treatment of mature osteoblasts induced only 
minimal effect on Runx2 expression, but had a positive effect on osteocalcin. This 
can be explained by the critical role of Runx2 in promoting and initiating the MSCs 
differentiation to osteoblasts. 
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However, osteocalcin (OC) is a known negative regulator of the differentiation 
process, which is normally expressed in the late stages (96, 124). 
In addition to the promoted osteogenic differentiation, the increased phosphory-
lation of Mitogen-activated Protein Kinase (MAPK) ERK1/2 and p38 was also 
detected in Strontium-treated MSCs (126).  
MAPK has a direct role in enhancing osteogenesis through the phosphorylation 
and subsequent activation of Runx2 (127). 
It has also been demonstrated, that Rat Sarcoma viral oncogene homolog (RAS), 
an upstream regulator of ERK1/2 and p38, was activated by Strontium treatment, 
and siRNA-mediated RAS knockdown inhibited Strontium-stimulated expression of 
osteogenic markers. Thus, Strontium could also stimulate the osteogenic 
differentiation of MSCs through activating the RAS/MAPK signaling pathway and 
the downstream transcription factor Runx2 (126). 
1.3.5. Differentiation, Activity and Apoptosis of Osteoclasts 
The suppressive effect of Strontium ranelate on osteoclasts is one the critical 
actions that play a major role in the Sr2+ mediated treatment of osteoporosis 
leading to a drop in bone resorption and the destructive process. S2+ has the 
ability to decrease the differentiation rate, the activity and total number of bone-
resorping osteoclasts though its pro-apoptotic effects (107-109).  
This effect was recently confirmed in a series of experiments. The number of 
mature osteoclasts derived from murine spleen cells and their resorbing activity 
were strongly suppressed after Strontium ranelate exposure in a process directly 
Fig.10. Shows the different types of bone cells with their related main functions. Osteoprogenitor 
cells are the main source of all bone cells. Osteoclasts are related to bone destruction and 
resorption, while osteoblasts induce a reversal action and lead to bone formation. Osteocytes are 
represented an inactive osteoblasts embedded in mineralized bone (125) 
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associated with the disruption of the actin cytoskeleton of the osteoclast-sealing 
zone (92).  
Moreover, monitoring the expression of carbonic anhydrase and fibronectin 
receptors after cells treatment with Strontium ranelate demonstrated its destructive 
action on osteoclasts (91). 
Several studies support the idea that the effect of Strontium ranelate is dose-
dependent and is exerted, at least partially, through a CaSr-dependent 
mechanism. The stimulation of Calcium-sensing receptors by Sr2+ has been 
demonstrated to be the underlying major mechanism of the cellular effects of 
strontium ranelate on these cells (128). 
This mechanism is mediated through direct activation of CaSr followed by 
stimulation of phospholipase C (PLC) and nuclear translocation of NF-қB. 
However, and in contrast of Ca2+, the effects of Sr2+ are mediated by activation of 
diacylglycerol (DAG)-PKCβII signaling and not by IP3-dependent signaling (80) 
(Fig.11). 
Fig.11. This diagram demonstrating the role of CaSR in both Ca2+ and Sr2+ induced apoptosis of 
mature osteoclasts: 
After stimulation by extracellular calcium, the CaSR activates PLC, which is responsible for the 
translocation of NF-қB from the cytoplasm to the nucleus in mature osteoclasts, in an IP3-
dependent manner.  
However, stimulation by extracellular strontium, the CaSR also activates PLC, which is, in turn, 
responsible for activation of the DAG-PKCβII signaling pathway, which in turn promotes 
translocation of NF-қB from the cytoplasm to the nucleus in mature osteoclasts but in an IP3-
independent manner. Activation of NF-қB can potentiate, leading to enhanced apoptosis of mature 
osteoclasts (80) 
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2. PROBLEM STATEMENT 
Insufficient or completely impaired production and expression of the Runx2 
transcription factor is the leading factor of the Cleidocranial Dysplasia syndrome. 
Such a mutation causes a deficiency or inhibition of osteoblast differentiation from 
mesenchymal stem cells and subsequent defects and deformities in both bone 
and tooth formation. 
Cleidocranial Dysplasia is frequently associated with various symptoms and 
characteristic features ranging from mild, in some cases not noticeable, symptoms 
to severe and challenging symptoms. Many patients are facing real difficulties in 
their daily life as a result of the skeletal deformations and possible other 
associated abnormalities such as muscular hypotonia and hearing loss. In 
addition, these patients suffer from esthetic problems due to the presence of 
supernumerary teeth, delayed eruption of permanent teeth, associated 
malocclusion and the hypoplastic maxilla responsible for the prognathic 
appearance of these patients. 
Treatment and management of the CCD symptoms is still a real challenge and 
subject of continuous research. Numerous studies aimed to find the best 
management methods of the associated symptoms some of which, however, still 
are untreatable and unmanageable.  
In view of the increasing number of affected patients worldwide and our 
experience with such cases at the Orthodontic Clinic of Regensburg University 
Hospital, new approaches to the management of the associated symptoms and 
their severity had to be considered. 
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3. AIM OF THE STUDY 
It is well-known that patients with Cleidocranial Dysplasia suffer from a mutation of 
the Runx2 gene which results in impaired bone formation and remodeling 
processes. Because of the high potential of Strontium in promoting the expression 
of Runx2 and other osteoblast-related genes and stimulating the differentiation of 
the mesenchymal stem cells into osteoblasts, we decided to apply this chemical 
compound to cells extracted from a patient with Cleidocranial Dysplasia syndrome.  
Due to its ability to improve osteoblast differentiation and, hence, bone formation, 
.Strontium is recognized and registered in the European Union (EU) for treatment 
of women with osteoporosis. Moreover, it shows a high potential to decrease bone 
resorption due to its depressive role in osteoclast formation and its promoting 
effect in osteoclast apoptosis. This dual effect has made Strontium the treatment 
of choice for osteoporosis.  
After reviewing an abundance of articles, we failed to find one single study about 
the use of Strontium in dentistry. Therefore, we aimed to explore the effects of 
Strontium on osteoblasts extracted from a patient with CCD and to demonstrate 
possible improvements in the expression of the Runx2 transcription factor or in 
osteoblast function. 
This pioneering treatment approach non only focuses on the management CCD 
symptoms, but rather promises to prevent the very development of the symptoms 
or at least to decrease their severity. If this experiment succeeds, further animal 
and clinical trials in the embryonic stages of development may improve the 
prospects of eliminating or limiting CCD symptoms and getting healthy kids from 
affected parents. 
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4. MATERIALS AND METHODS 
4.1. Cell Culture 
4.1.1. Isolation of the Osteoblasts 
Primary Runx2 +/- osteoblasts were obtained from human alveolar bone following 
appropriate informed consent of a patient with Cleidocranial Dysplasia. The 
analysis of genomic DNA of the patient revealed a mutation in the runt-domain of 
the Runx2 gene and confirmed his/her affection with the CCD syndrome. The 
patient also exhibits characteristic symptoms of CCD such as supernumerary 
teeth, brachycephaly, and brachydactyly. 
4.1.2. Growth Conditions 
The primary cell line was enchriched and cultivated in osteoblast growth medium 
(Provitro/Germany), which was supplied with 10% heat-inactivated fetal bovine 
serum and 50 µg/ml ascorbic acid, at 37oC with 5% CO2. The cells were then 
obtained in the third passage and were cryopreserved and stored in liquid nitrogen 
until use. 
In order to compare the effect of Strontium on Runx2+/- osteoblasts, we cultivated 
these cells in absence or in presence of 3 mM Strontium chloride SrCl2 
(Merck/Germany) for 10 days in cell culture medium. 
4.1.3. Cells Proliferation 
Osteoblasts were seeded in 96-well plate at a concentration of 2,800 cells per well 
in 100 µl cell culture medium. In order to observe the proliferative effect of 
Strontium, we added SrCl2 up to a concentration of 3 mM to the cells (tested 
group) or we excluded Sr2+ from the cells culture medium (control group). 10 µl 
WST-1 (Roche/Switzwerland) was added per well to both of test and control group 
and the cells were incubated at 37oC with 5% CO2 for a maximum time of 3 hours. 
The increasing absorbance (A=450 nm) of the sample corresponds to the 
increasing cell number. Absorbance was determined in 1 hour interval from 0 to 4 
hours using a microplate reader (Mod. GENios, Fa. TECAN/Austria). 
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Counting the number of the cells and confirming their concentration and density 
was done using a Hemocytometer 
(Fig.12): It consists of a thick glass 
microscope slide with a rectangular 
indentation that creates a chamber. This 
chamber is engraved with a laser-etched 
grid of perpendicular lines. The device is 
carefully crafted so that the area 
bounded by the lines and the depth of 
the chamber are known. Thus, it is possible to count the number of cells or 
particles in a specific volume of fluid, and thereby calculate the concentration of 
cells in the fluid overall. 
The concentration or density of the osteoblasts was calculated using this formula: 
 
 
 
4.1.4. Alkaline Phosphatase (ALP) Activity Measurement 
This biomedical assay was used for measuring alkaline phosphatase ALP activity 
is osteoblasts culture samples after been exposed to 3 mM Sr2+. The commercially 
available cytochemical kit (QuantiChromTM Alkaline Phosphatase Assay Kit [DALP-
250], BioAssay Systems-USA) has been used, in which ALP at alkaline pH 
catalyses the following reaction: 
 
Dimensions Area 
Volume at 0.1 mm 
depth 
1 x 1 mm 1 mm2 100 nl 
0.25 x 0.25 mm 0.0625 mm2 6.25 nl 
0.20 x 0.20 mm 0.04 mm2 4 nl 
0.05 x 0.05 mm 0.0025 mm2 0.25 nl 
                                                  
ρ-nitrophenyl phosphate + H2O                                        ρ-nitrophenyl + Pi   
    (Colorless in Alkali)                                                        (Yellow in Alkali)  
 
                Catalyzing effect of ALP 
 
Number of cells counted 
(Proportion of chamber counted)(Volume of 
chamber) 
Volume of sample dilution 
Volume of original mixture is sample 
Fig.13. Diagram of the hemocytometer grid used to count the number of the tested cells. Note that 
the different colors represent different dimensions and depths as showed in the adjacent TABLE 2
(129) 
Fig.12. A hemocytometer with the main parts: 
1. Sample introduction point, 2. Counting 
chambers, 3. Cover glass (129) 
1 2 
3 
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Fig.14. 
A. Tecan spectrophotometric plate reader which was used in our study, from GENios, Austria (131) 
B. The 96-well microtiter plate used 
Confluent adherent cells were trypsinised and counted with a Neubauer-Chamber. 
Then, 500,000 cells of the test group (3 mM Sr2+) or control group (0 mM Sr2+) 
were gently lysed in 100 µl CelLytic ™M Cell Lysis Reagent (Sigma/USA) for 20 
minutes at 250C. Cell debris was removed by centrifugation (13,500g, 40C, and 15 
min.) of the cell lysat. The volume activity of the alkaline phosphatase was 
analyzed using a colorimetric assay and normalized to cell number (Sabokbar et 
al. 1994). 
Calculation of ALP activity of the sample (IU/L= nmol/(ml*min)) was done using the 
following formulas: 
 
 
 
 
 
4.1.5. Biomineralization Assay According to Gregory et.al. 
Mineralization of confluent cells was determined by fixation with 10% 
formaldehyde at room temperature for 15 minutes and subsequent Alizarin red-S 
staining and quantification as described by Gregory et al. (2004) (132). 
 
(OD Sample t – OD Sample 0) * 1000 * Reaction Vol. 
= 
t *  * l * Sample Vol. 
(OD Sample t – OD Sample 0) * Reaction Vol. 
      = 
(OD Calibrator – OD H2O) * Sample Vol. * t 
OR 
A B 
x 35.3 
ODSample t and ODSample 0 are OD405nm values of sample at time t and 0 min. The factor 1000 
converts mmol/L to µmol/L. t is the incubation time (min). For ρ-nitrophenol,  = 18.75 mM-1×cm-1. l 
(light path, cm) is 1 cm for cuvette, and calculated for 96-well assay from the Calibrator, l = (OD 
Calibrator - OD H2O)/( *c) 
(130) 
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4.2. Applied Molecular Biological Methods 
4.2.1. RNA Isolation (TRI-reagent) 
Adherent confluent cells, which were grown in 
absence or presence of 3 mM Sr2Cl for 10 days, 
were rinsed with 1 ml TRI-Reagent (Sigma/USA) 
and further processed according to the 
manufacturer’s recommendations to isolate the 
RNA. The yield of the total RNA was determined 
using Picodrop™ µl spectrophotometer 
(Picodrop/UK) at 260 nm. 500 ng of total RNA 
were applied for cDNA synthesis 
(QuantiTeck®Reverse Transcriptase, Qiagen/ 
Germany). 
4.2.2. cDNA Synthesis 
This procedure was performed according to the description in the QuantiTect® 
Reverse Transcription handbook supplied by QIAGEN ™ 
1. Template RNA was placed on ice, whereas gDNA Wipeout Buffer, Quantiscript 
Reverse Transcriptase, Quantiscript RT Buffer, RT Primer Mix, and RNase free 
water were left at room temperature (15–25°C). All components were 
centrifuged before use and placed on ice. 
2. The genomic DNA elimination reaction was prepared on ice as described in the 
following table: 
  TABLE 3. Components of the gDNA elimination reaction according to GIAGEN ™ 
   
Component Volume/reaction Final concentration 
gDNA Wipeout Buffer, 7x 2 µl 1x 
Template RNA Variable (up to 1 µg*)  
RNase-free water Variable  
Total volume 14 µl – 
3. The reaction was incubated for 2 min at 42°C, and then placed on ice 
immediately. 
Fig.15. Picodrop™ µl Microliter 
Spectrophoto-meter for use with
Disposable UVpette Tips (133) 
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4. The reverse-transcription master mix was prepared according to the following 
table: 
TABLE 4. Components of the reverse-transcription master mix according to GIAGEN ™ 
   
Component Volume/reaction Final concentration 
Reverse-transcription master mix: 
Quantiscript Reverse Transcriptase   1 µl  
Quantiscript RT Buffer, 5x 4 µl 1x 
RT Primer Mix 1 µl  
Template RNA: 
Entire genomic DNA elimination 
reaction (step 3) 
14 µl (add at step 5) 
 
Total volume 20 l – 
 
5. Template RNA obtained from step 3 (14 µl) was added to each tube containing 
reverse transcription master mix. 
6. The reaction tubes were incubated for 15 min at 42°C, and then incubated for 3 
min at 95°C to inactivate Quantiscript Reverse Transcriptase. Reverse-
transcription reactions were stored on ice and directly preceded real-time PCR. 
 
 
 
 
Fig.16. Diagram summarizing the stepwise process of cDNA synthesis from RNA with coincidental 
elimination of genomic DNA for quantitative real time PCR (134) 
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4.2.3. Real Time PCR 
Real time PCR was performed using the DyNAmo™ Sybr Green q-PCR Kit 
(Finnzymes/Finland) in triplets for each cDNA on Abi7000 (Applied 
Biosystems/USA). The real time amplifications included an initial step of 10 
minutes at 95oC (polemerase heat activation), followed by 40 cycles at 95oC for 10 
seconds (denaturation), 65oC for 30 seconds (annealing / elongation / data 
collection). This technique allows the identification of the cycling point where the 
PCR product is detectable by means of 
fluorescence emission (threshold cycle or 
Ct value). Moreover, a dissociation curve 
was obtained after each Real time PCR 
run in order to exclude false-positive 
signals that might be caused by primer 
dimmers. Gene expression was 
calculated using the software tool REST 
2005 (Pfaffl et al., 2002). Appropriate 
primers (Table 5) were chosen by use of 
the online-program “Primer3” (http://biotools.umassmed.edu/bioapps/ 
primers_www.cgi). 
TABLE 5. Polymerization chain reaction (PCR) primers used in this study, supplied by Eurofins, 
Germany. The accession numbers are: NM_167214.1, NM_000478.3 & NM_199173.3 
respectively. ALP: Alkaline Phosphatase, OCN: Osteocalcin 
   
Name Forward Reverse 
18S rRNA 5’-ACGGGGAATCAGGGTTCGAT-3’ 5’-TTGCCCTCCAATGGATCCTC-3’ 
ALP 5’-CCACAAGCCCGTGACAGATG-3’ 5’-TTTGGCCCTTGGGGAAGATT-3’ 
OCN 5’-GGAGGGCAGCGAGGTAGTGA-3’ 5’-ACCCTAGACCGGGCCGTAGA-3’ 
Agarose Gel Electrogenesis: The gel was prepared using 60 ml of 1xTBE (gel 
buffer) with 120 mg of Biozym LE-Agarose powder (2% agarose gel). The mixture 
was left to boil at 200°C. After reaching the boiling point and complete dissolving 
of the agarose, the mixture was removed and left to cool a little at room 
temperature. Then, 2 µl of ethidium bromide solution (EtBr, 5mg/µl), which 
intercalates between DNA base pairs and fluoresces when activated with UV 
radiation, was pipetted into the mixture and mixed by shaking.  
Fig.17. Machine used for q-PCR, from 
Stratagene-Mx3005®, Germany (135) 
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10 µl of the sample was taken and mixed with 4 µl of dye buffer with a known 
migration rate and then placed in the well within the gel. The gel was allowed to 
set and, then, electrophoresis was carried out with the gel submerged under 
buffer. The machine was adjusted at 90 V for 60 min. Bands of DNA fluorescence 
were examined under ultraviolet radiation. 
4.3. Statistics 
Data analysis was performed using Student’s t-test, when appropriate. Otherwise, 
a Wilcoxon-Mann-Whitney test was employed. Statistical analysis was performed 
with the SPSS software. Probability values of p ≤ 0.05 were regarded to be 
significant. 
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5. RESULTS 
5.1. Gene Expression Analysis of Runx2-Responsive Genes 
Various studies noted that Strontium ranelate improves bone quality by increasing 
bone formation and decreasing bone resorption rates (88-94). SR acts by means of 
activation of Runx2 genes and other osteoblastic genes through a Calcium-
sensing receptors mechanism (89). We analyzed, therefore, the gene expression of 
two Runx2-responsive genes: alkaline phosphatase (ALP) and osteocalcin (OCN), 
which play a major role in the mineralization process of the bone. 
The gene expression of the experimented osteoblastic genes in Strontium-
exposed Runx2+/- osteoblasts (test group) was up-regulated 1.3 fold for ALP and 
1.1 fold for OCN. The following tables show the measurements of gene 
expression of ALP, OCN and 18S rRNA in both the test and the control group. 
TABLE 6. These tables demonstrate the measurements of the tested osteoblastic genes’ 
expression. The left table shows gene expression in 3 mM Sr2+ exposed Runx2+/- osteoblasts, 
whereas the right table shows the control group not exposed to Sr2+. Notice from the last table, the 
significant up-regulation of ALP and OCN compared to 18S rRNA 
Osteoblasts exposed in 3 mM Strontium  Osteoblasts without Strontium 
 Alkaline Phosphatase mean   Alkaline Phosphatase mean 
1 28,67 28,87 28,73 28,756  1 30,65 30,01 29,78 30,146 
2 29,55 29,06 29 29,203  2 29,96 29,93 29,69 29,86 
3 30,29 29,83 29,71 29,943  3 29,94 30,03 29,39 29,786 
4 29,38 29,14 28,85 29,123  4 29,42 29,24 28,94 29,2 
 Osteocalcin mean   Osteocalcin mean 
1 26,28 26,07 26,34 26,23  1 26,63 26,67 26,6 26,633 
2 26,33 26,4 26,14 26,29  2 26,61 26,63 26,6 26,613 
3 26,82 26,76 26,64 26,74  3 26,29 26,38 26,45 26,373 
4 26,35 26,52 26,32 26,396  4 26,68 26,65 26,4 26,576 
 18S rRNA mean   18S rRNA mean 
1 9,82 10,11 9,86 9,93  1  9,72  9,8  9,79  9,77 
2 9,88 10,03 10,25 10,053  2 10,38 10,52 10,37 10,423 
3 10,15 10,31 10,3 10,253  3  9,93  9,7  9,8  9,81 
4 10,34 10,18 10,2 10,24  4 10,02 10,24 10,04 10,1 
   mean 10,119     mean 10,025 
   Sdv 0,1556     Sdv  0,303 
           
Gene Reaction Effici. Expres. Std. Error 95% C.I. P(H1) Result 
18S rRNA 0,5 1,000 0,865 - 1,137 0,816 - 1,300 1,000  
ALP 0,5 1,268 0,969 - 1,629 0,727 - 2,074 0,012 UP 
OCN 0,5 1,097 0,980 - 1,197 0,884 - 1,303 0,049 UP 
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This change of gene expression was found to be statistically significant for ALP 
(p=0.012) and OCN (p=0.049). At the same time, gene expression of the 
housekeeping gene, 18S ribosomal RNA, which was used as a standard (control) 
gene for comparison purposes, was not changed (p=1.0) (Fig. 18). 
 
 
 
 
 
 
 
 
 
 
 
5.2. Measurement of ALP Activity 
Moreover, we analyzed the phenotype of confluent Runx2+/- osteoblasts in 
presence of 3 mM Sr2+ in order to counter-check the validity of previously obtained 
gene expression data (Section 5.1). For that reason, we determined the volume 
activity of ALP normalized to the cell number. We found in 3 mM Sr2+ exposed 
Runx2+/- osteoblasts a statistically significant 1.3 fold increase of ALP activity to 
20.4 ± 2nmol/min x ml x 100,000 cells in comparison to osteoblasts in non-
Strontium, 0 mM Sr2+, containing osteoblast growth medium (control group) 
(p=0.02) (Fig. 19). 
 
 
 
Fig.18. The boxes represent the interquartile range, or the middle 50% of observations. The 
dotted line represents the median gene expression. Whiskers indicate the minimum and maximum 
observations. The red, blue and yellow boxes represent 18S rRNA, ALP & OCN gene expression 
respectively with significant gene up-regulation for ALP and OCN 
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Fig.19. Significant up-regulation of ALP in a certain volume in 3 mM Sr2+ treated osteoblasts 
compared to 0 mM Sr2+ treated osteoblasts  
Fig.20. Kinetics of ALP reaction in 96-well plate assay. Note that the first three curves represent 
the osteoblast groups treated with Strontium ranelate (+). These groups are marked with the 
colors: green, red and blue. The other three curves marked with orange, purple and yellow 
represent the osteoblast control groups (-) 
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5.3. Estimation of Biomineralization Activity 
In addition to the ability of Strontium to improve osteoblastic genes expression, it 
can also increase osteoblast replication, osteoblast differentiation and bone matrix 
synthesis and mineralization (89, 90, 93, 103).  
We estimated the ability of strontium to improve the biomineralization of confluent 
Runx2+/- osteoblasts in presence or absence of 3 mM Sr2+. Dyeing of extracellular 
matrix with Alizarin-Red S revealed a statistically significant improvement of the 
mineralization of Strontium-exposed Runx2+/- osteoblasts in comparison to the 
Strontium-excluded cell culture (Fig. 21), which validates the results of Real time 
PCR. 
  
 
 
 
 
 
 
 
 
 
 
Fig.21. Effect of 3mM Sr2+ presence on biomineralization activity. Alizarin-Red S dye was used to 
measure the bio-mineralization rate in the extracellular matrix. The test demonstrated a significant 
improvement in the extracellular bio-mineralization in the presence of 3mM Sr2+ comparing to the 0 
mM Sr2+ control group 
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5.4. Effect of SrCl2 on Cell Proliferation Rate 
Runx2 has a critical role in osteoblast differentiation, function and, consequently, 
in bone biology (31). Since Sr2+ has a stimulating effect on osteoblast differentiation 
and maturation, the effect of Strontium in Runx2+/- osteoblasts was tested. 
The increase of cell number corresponds with the conversion of WST-1 to 
formazane, which is detectable at 450 nm (Fig.22). The observed 1.3 fold 
accelerated growth of Runx2+/- osteoblasts in presence of 3 mM Sr2+ from the 1st 
day up to the 3rd day demonstrates the growth supporting effect of Strontium on 
the exposed cells as compared to the 0 mM Sr2+ control group. 
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Fig.22. Effect of 3mM Sr2+ presence on the cell proliferation rate. Formazane formation was 
detected at 450nm and used to reflect the cells proliferation process. Proliferation was measured 
for three days and the results demonstrated improvement in the cell proliferation rate in presence 
of 3mM Sr2+ as compared to the 0 mM Sr2+ control group 
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6. DISCUSSION 
Runx2 is considered to be the master transcription factor and the key gene of 
bone tissue. It plays a major role in all phases of bone formation and is 
responsible for the initial turnover of pluripotent mesenchymal stem cells into 
osteoblasts (29). As well, its presence controls the proliferation, differentiation, and 
maintenance of these cells (16, 30, 31). In the dental area, Runx2 is very essential to 
the development of calcified tooth tissue, the proliferation of the dental lamina and 
the maintenance of tooth formation in the later stages (31-33). Furthermore, Runx2 
regulates the alveolar remodeling process, which is essential for tooth eruption 
and may play a role in the maintenance of the periodontal ligament integrity (29). 
Ectopic expression of Runx2 in mesenchymal cell lines leads to up-regulation of 
various osteoblast-related genes like osteocalcin, alkaline phosphatase, 
collagenase-3, bone sialoprotein and collagen type I (30). This effect enhances the 
role of Runx2 in bone formation and remodeling. 
It was shown that homozygous mice with a mutated Runx2 gene have a complete 
lack of ossification and both intramembranous and endochondral ossifications are 
totally blocked due to the maturational arrest of osteoblasts (35) which could result 
in newborn lethality (22). As a result, Runx2-knockout mice display an absence of 
osteoblasts and bone formation, while the heterozygous mice (loss-of-function 
mutations) show specific skeletal abnormalities that are very similar to and 
characteristic of the human heritable skeletal disorder, Cleidocranial Dysplasia 
(CCD) (36). Lou et al. (2009) clearly proved using genetically engineered mouse 
models that a critical level of Runx2 functional activity is necessary to maintain 
normal osteoblast differentiation and an adequate bone formation process 49. 
However, tissue-specific over-expression of Runx2 in transgenic mice leads to 
osteopenia, decreased bone mineral density and multiple fractures and bony 
defects (52). These findings were very sensitive and demonstrated the importance 
of regulation of Runx2 expression and its activity in bone pathology and biology. 
They also highlight the fact that any mutations in the Runx2 gene (heterozygous or 
homozygous) may cause impairment and a wide range of defects in both the 
biological and medical level.  
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It has been hypothesized, that successful activation of Runx2 would lead to 
improvement of osteoblast differentiation and proliferation, upregulation of 
osteoblasts-related genes expression and promote ossification in bone formation. 
As a result, phenotypical symptoms of Cleidocranial Dysplasia may be prevented 
or at least minimized.  
Because of the well-known beneficial effects of Strontium on bone formation and 
remodeling, we decided to examine the effect of Strontium on primary Runx2+/-
osteoblasts which were extracted from a Cleidocranial Dysplasia patient affected 
with a heterozygous mutation in the Runx2 gene.  
In this study, we used Strontium chloride (SrCl2) instead of Strontium ranelate, 
because it exhibits very similar effects and properties in animal trials and can be 
easy dissolved in water which makes its laboratory use and application more 
reliable (136, 137).  
For investigating the effect of Strontium on Runx2+/- osteoblasts we decided to 
examine gene expression of two characteristic osteoblast-related genes, alkaline 
phosphatase and osteocalcin. Both gene products are involved in bone tissue 
formation and mineralization. ALP is highly essential for bone mineralization 
through hydrolyzing pyrophosphate, which antagonizes the formation of hydroxyl-
apatite (138), whereas OCN which is produced exclusively by osteoblasts is 
believed to play a promoting role in nucleation of hydroxyapatite crystals (139). 
A statistically significant up-regulation of osteoblast marker genes, ALP and OCN 
was recorded.  This result was positively confirmed by the Alizarin Red S staining 
test of the mineralization rate in the extracellular matrix. Improvement in the 
mineralization of the extracellular matrix of Strontium-exposed Runx2+/- osteoblasts 
was demonstrated. Moreover, determination of enzyme activity of ALP in the 
Strontium-exposed Runx2+/- osteoblasts revealed significantly more activity than in 
cells grown without Strontium. This raise in ALP expression was time-related, 
which means ALP expression increased with time. Thus, the constant and 
continuous stimulation effect of Sr2+ on the osteoblasts was confirmed.  
Similar observations of improved mineralization of extracellular matrix and ALP 
activity were previously made in Strontium-exposed mesenchymal cells or in pre-
osteoblasts from rodent origin. Strontium administration has also shown in vivo 
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positive results regarding bone formation and enhanced remodeling. Previous 
studies reported that the exposure of osteoblasts to strontium results in an up-
regulation of Runx2 gene expression (140). However, in this experiment, we 
observed no statistically significant change of gene expression of Runx2 in the 
primary cell culture (data not shown). In fact, significant up-regulation of gene 
expression was limited to ALP and OCN without any considerable change of 
Runx2 expression.  
These findings may be explained by the promoting effect of Runx2 in the 
differentiation of pluripotent mesenchymal stem cells into osteoblasts, and its 
inhibiting role in their maturation. It has been previously noticed that pre-osteo-
blasts express Runx2 abundantly in the early stages of cells differentiation. Later, 
however, it will be down-regulated by immature osteoblasts. In mature cells Runx2 
exerts an inhibiting effect on terminal differentiation, and therefore, is not 
expressed anymore by these cells (57), which may explain the insignificant 
improvement in Runx2 expression in this study.  
In 2007, a similar experiment by Zhu LL et al. was done on mesenchymal stem 
cells, where an increase in the transcriptional activity and phosphorylation level of 
Runx2 gene, but not of osteocalcin (96) was noticed. At the same time, experiments 
on mature osteoblasts showed only a minimal effect on Runx2 expression, but had 
a positive effect on osteocalcin expression. It has been hypothesized that this 
might be due to the major role of Runx2 in promoting and initiating the MSCs 
differentiation to osteoblasts, whereas osteocalcin is a negative regulator of the 
differentiation process and is normally expressed in the late stages of osteoblast 
maturation (96, 124). We assume that the observed up-regulation of alkaline 
phosphatase and osteocalcin genes might be due to the promoting effect of the 
transcription factor Runx2 in the expression of both tested osteoblast-related 
genes (141, 142) and result from allosterical activation of already existing Runx2 
protein, but not a positive effect of Runx2 expression. 
With respect to structure, Runx2 has a C-terminal proline/serine/threonine-rich 
region (46). This domain mediates ERK/MAPK1 responsiveness, whereas 
phosphorylation of specific serine-residues leads to enhanced transcriptional 
activity of Runx2 (127, 143). Moreover, it has been demonstrated that Strontium 
activates the phosphorylation activity of the MAPK signaling pathway, which in turn 
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promotes the transcriptional activity of Runx2 in human mesenchymal stem cells 
(126). Similar effects of allosterically activation of Runx2 by MAPK were also 
reported in human embryonic kidney (HEK293) cells and in murine calvaria 
osteoblasts treated with Strontium (121, 144). The osteoblastic growth-supporting 
effect of Strontium to Runx2+/- osteoblasts was clearly evidenced in this investi-
gation. Similar findings suggesting that Strontium preferentially stimulates cell 
replication in cells of osteoblastic lineage have been reported (93).  
Thus far, the mechanism of how Strontium stimulates cell replication and the 
corresponding signaling pathways is little known and subject of further basic 
research (145). 
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7. SUMMARY 
This trial provides valuable impulses and information for pharmacological and 
clinical research aiming to treat, or at least decrease the severity of Cleidocranial 
Dysplasia symptoms. Until now, Strontium ranelate was exclusively recognized for 
treatment of osteoporosis in postmenopausal women or for osteoblast growth 
stimulation for cell biological laboratory purposes. However, we assume, on the 
basis of this first pilot study and the significant improvement in Runx2+/- osteoblast-
related genes (ALP and OC), cell proliferation rate and the rise of mineralization in 
extracellular matrix, that administration of Strontium during embryogenesis and 
postnatal development by Cleidocranial Dysplasia patients would significantly 
improve bone formation of the clavicles, accelerate the closure time of fontanels in 
children and decrease the hazard of bone deformations.  
At the same time, we are still aware of potential risks of Strontium due to its 
inhibiting action of osteoclastogenesis and stimulating effect on osteoclast 
apoptosis which might interfere with the adaptive bone remodeling process during 
postnatal growth. Therefore, we recommend further investigations on Strontium 
administration with genetically engineered Runx2+/- mice to evaluate the risk-
benefit profile of Strontium in the phase of embryogenesis. 
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10. Zusammenfassung 
10.1 Einleitung 
10.1.1 Die Dysostosis cleidocranialis 
Das Dysostosis Cleidocranialis Syndrom (DCC) ist durch verschiedene Namen, 
wie Marie Sainton Syndrom, Mutation Dysostose und Cleidocranial Dysplasia  
bekannt. Als Dysostosis cleidocranialis wird eine seltene, autosomal-dominante, 
generalisierte skelettale Dysplasie, welche sich nicht nur auf der kraniofazialen 
Region beschränkt bezeichnet (1).  
DCC wird in allen ethnischen Gruppen beobachtet und zeigt keine 
geschlechtsspezifische Prädisposition. Eines der charakteristischsten Merkmale 
der DCC sind die hypoplastisch oder aplastisch angelegten Schlüsselbeine, die 
eine Hypermobilität der Schultern bewirken (4, 5).  
Die DCC ist ein hereditäres Fehlbildungssyndrom, das hauptsächlich die desmale 
Ossifikation des Schädels und die Ossifikation der Schlüsselbeine betrifft. Die 
Inzidenz wird auf 1 pro 200.000 Lebendgeburten geschätzt (6), die Prävalenz liegt 
bei 1:1.000.000 (7) 
Das Syndrom weist andere assoziierte Anomalien, wie kraniofaziale 
Fehlbildungen, Zahnüberzahl (bis 70 Zähne bei einigen Patienten)(8), die 
Anwesenheit von mehreren retinierten oder verlagerten Zähnen und die 
Persistenz der Milchzähne bei Dentitio tarda sowie die Hypoplasie des 
Mittelgesichtes auf. Trotz weiterer skelettaler Befunde sind es vor allem die 
kraniofazialen Merkmale, die eine Diagnose ausschließlich durch den 
zahnärztlichen Befund ermöglichen (9). 
Ein anderes typisches Merkmal der DCC, ist der verzögerte oder ausbleibende 
Verschluss der Nähte des Schädels (10, 11).  
Die genetische Ursache der Dysostosis DCC ist eine Mutationen des Runx2 Gens 
(osteoblast specific transcription factor) (12), welches auf dem kurzen Arm des 
Chromosoms 6 (6p21) lokalisiert ist (13). Das Genprodukt gehört zur Gruppe der 
Runt-Transkriptionsfaktoren – die an der Transkription spezifischer Gene beteiligt 
sind. Runx2 ist unter anderen an der Reifung der mesenchymalen Zellen zu 
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Osteoblasten beteiligt (14). Runx2 spielt auch die Schlüsselrolle in der 
Osteogenese. Zahlreiche Publikationen belegen, dass Runx2 ein integraler 
Bestandteil vieler Prozesse ist, die während den verschiedenen Phasen der 
Knochenentwicklung und Knochendifferenzierung ablaufen. (15)  
Unter anderem reguliert Runx2 die Zellproliferation und kontrolliert die 
Differenzierungsprozesse von mesenchymalen Zellen zu Osteoblasten (14, 16, 17). 
Die Rolle in der Mineralisierung von Zahnhartsubstanz und der Einfluss auf die 
Proliferation der Zahnleiste macht Runx2 zu einem sehr wichtigen Faktor in der 
Dentino- und Amelogenese (14, 18, 19).  
Die unzureichende Gendosis an funktionellem Runx2 ist der entscheidende Faktor 
der DCC. Dies führt zu einem Mangel bzw. zu einer Hemmung der Differenzierung 
der mesenchymalen Stammzellen zu Osteoblasten und damit zu den bekannten 
skelettalen Defekten. 
 
10.1.2. Die Wirkung von Strontium auf den Knochenmetabolismus 
Strontium, das als Strontiumranelat (Protelos®) zur Behandlung bzw. Vorbeugung 
von Osteoporose seit relativ kurzer Zeit eingesetzt wird, verfügt über einen dualen 
Effekt in Bezug auf Knochenabbau bzw. Knochenaufbauprozessen (21,31,36). In 
vitro-Studien an Osteoblasten zeigten, dass Strontium den Calcium-sensing 
Receptor (CaSR), sowie die Synthese von Prostaglandin E2 stimuliert, wodurch 
eine Aktivierung des MAPK-Signalweges erfolgt (31). Die durch Strontium 
induzierte Aktivierung des MAPK-Signalweges in Osteoblasten führt zu einer 
vermehrten Bildung von charakteristischen Knochenmarkerproteinen (z.B. 
alkalische Phosphatase, Kollagen Typ I, etc.) und damit zu einer verbesserten 
Mineralisierung der extrazellulären Matrix (31). 
Übersicht über die Wirkung von Strontium auf den Knochenmetabolismus: 
1.  Senkung der Inzidenz von Wirbel- und Hüftknochenfrakturen (22, 23) 
2.  Beeinflussung des Knochenumbauprozesses durch eine Erhöhung der 
Knochenbildung und die Verringerung der Knochenresorption (21) 
3. Steigende Knochenfestigkeit und Knochenmasse und allgemeine 
Verbesserung der Qualität der Knochenstruktur (31, 28, 32-35) 
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4. Stimulierung der Differenzierung von mesenchymalen Zellen zu Osteoblasten 
und Beschleunigung der Reifung der Osteoblasten (25, 26) 
5. Erhöhung der Synthese von Kollagen Typ I und Förderung der Mineralisierung 
der Knochenmatrix (36) 
6. Unterdrückung der Bildung und Funktion von Osteoklasten und Förderung der 
Apoptose (25) 
10.1.3. Ziel der Doktorarbeit 
Bisher ist keine Studie über den Einsatz von Strontium an DCC – Patienten 
bekannt. Aufgrund der in der wissenschaftlichen Literatur beschriebenen Wirkung 
von Strontium, die zur zusätzlichen Aktivierung von Runx2 durch 
Phosphorylierung führen, wäre es denkbar, dass die Ossifikationsleistung der 
Runx2+/--Osteoblasten unter der Wirkung von Strontium verbessert werden 
könnte. Im Rahmen dieser Doktorarbeit wurde deshalb die Wirkung von Strontium 
an DCC Osteoblasten untersucht, um weitergehende Versuche an geeigneten 
Tiermodellen (z.B. Runx2+/--Mäusen) vorzubereiten. 
10.2. Material und Methoden 
10.2.1. Zellkultur 
Nach dem Erhalt der entsprechender Einwilligung des Patienten mit Dysostosis 
cleidocranialis, wurden Runx2+/- Osteoblasten aus menschlichem Alveolarknochen 
isoliert und angereichert. Die Analyse der genomischen DNA der Patienten zeigte 
eine Mutation im Runx2 -Gen und bestätigte die Erkrankung am DCC Syndrom. 
Die Runx2+/- Zellen wurden in einem Nährmedium mit 10%igem Rinderserum und 
50 µg/ml Ascorbinsäure, bei 37°C mit 5% CO2 angereichert 
(Provitro/Deutschland). 
10.2.2. Molekularbiologische Arbeitsmethoden 
Die Gesamt-RNA wurde mit dem Tri-Reagent extrahiert. Die gewonnene RNA 
wurde hinsichtlich der Ausbeute und Reinheit mittels eines UV/Vis-
Spektralphotometers (PicoDrop) überprüft. 1 µg Gesamt-RNA wurde mittels einer 
reversen Transkriptase in cDNA umgeschrieben. Die cDNA wurde danach mittels 
Real-time-PCR und geeigneter PCR-Primer mit einem „Stratagene MX3000P 
ZUSAMMENFASSUNG  60 
 
 
qPCR-System“ analysiert. Aus den aufgezeichneten Floureszenzschwellenwerten 
(CT-Werten) wurde nach der von Livak et al. (2001) publizierten ∆∆CT-Methode 
ein Genexpressionsverhältnis berechnet. 
10.2.3. WST-1-Test 
Um die Wirkung von Strontium auf Runx2+/- Osteoblasten zu beurteilen, wurden 
diese Zellen in Abwesenheit (Kontrollgruppe) oder in Gegenwart (Testgruppe) von 
3 mM Strontiumchlorid (SrCl2)  für 10 Tage auf einer 96-Well-Platte, bei einer 
Konzentration von 2.800 Zellen pro Well in 100 ul Zellkulturmedium (Merck / 
Deutschland) kultiviert. 
Anschließend wurden 10 ul WST-1 (Roche),  sowohl dem Test- und 
Kontrollmedium beigefügt und die Zellen wurden bei 37°C mit 5%igem CO2 für 
eine maximale Zeit von 3 Stunden inkubiert. Die zunehmende Absorption (A = 450 
nm) der Probe entspricht der zunehmenden Anzahl an vitalen Zellen. 
 Die Absorption wurde im 1-Stunden-Abstand (0-4 Stunden) mit Hilfe eines 
Plattenlesegerätes (Mod. GENIOS, Fa.TECAN/Österreich) ermittelt. 
 
10.2.4. Alkalischer Phosphatase Test 
500.000 Zellen der Test (3 mM Sr2+, 6 Proben) - und Referenzgruppe (0 mM Sr2+, 
6 Proben) wurden in 100 µl eines Zell-Lysepuffers (CelLytic, Sigma-Aldrich) lysiert. 
Die Zelltrümmer wurden bei 4°C in einer Tischzentrifuge bei 14000 rpm 
abzentrifugiert. 50 µl von dem Zellüberstand wurden mittels einem alkalischen 
Phosphatase-Test (ALP) zur Messung der enzymatischen Aktivität 
(QuantiChromTM Alkaline Phosphatase Assay Kit , BioAssay Systems-USA)  
verwendet.  
 
10.2.5. Biomineralisierungsassay nach Gregory et al (1994) 
Durch ein Biomineralisierungsassay nach Gregory et al. (1994) wurde die mit 3 
mM Strontium behandelte Testgruppe (n=6) mit 10%igem Formaldehyd fixiert und 
mit 2%iger Alizarinrot-S angefärbt. Dieser Farbstoff bindet spezifisch fest an 
kalzifizierter extrazellulärer Matrix. Die fixierten und gefärbten Zellmonolayer 
wurden nach dem Abwaschen mit Wasser durch einen Spatel abgekratzt und der 
Farbstoff durch Eisessig in Verbindung mit einer 10 minütigen Inkubation bei 85°C 
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extrahiert. Die Absorption des extrahierten Farbstoffs wurde bei 405 nm gemessen 
und mit den Absorptionswerten der Kontrollgruppe (0 mM Strontium, n=6) 
verglichen und statistisch (U-Test) ausgewertet. 
 
10.2.6. Statistische Auswertung 
Die Datenanalyse erfolgte mittels (Student's t-Test), wenn es möglich war, 
ansonsten über den (Wilcoxon Mann Whitney-Test). Die statistische Auswertung 
wurde mit dem Programm SPSS durchgeführt. Die Wahrscheinlichkeits-Werte 
wurden von p ≤ 0,05 als signifikant angesehen. 
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10.3. Resultate 
10.3.1. Genexpressionsanalyse 
Die Genexpression der Osteoblasten wurde 1,3 fach für ALP und 1,1 fach für OCN 
verbessert. Diese Veränderung der Genexpression wurde als statistisch signifikant 
für ALP (p = 0,012) und OCN (p = 0,049) angemessen. Gleichzeitig, wurde  die 
Genexpression des Housekeeping-Gens (18S rRNA), das als Referenzgen für die 
Zwecke des Vergleichs verwendet wurde, nicht geändert (p = 1,0). (Abb. 1) 
 
 
 
 
 
 
 
 
  
 
 
 
Analysiert wurde der Phänotyp von Runx2+/- Osteoblasten in Gegenwart von 3 mM 
Sr2+. Das Volumen der ALP-Aktivität wurde auf die Anzahl der Zellen normalisiert. 
Es zeigte sich in 3 mM Sr2+ ausgesetzten Runx2+/- Osteoblasten ein statistisch 
signifikanter 1,3 facher Anstieg der ALP-Aktivität auf 20,4 ± 2nmol/min x ml x 
100.000 Zellen im Vergleich zu non-Strontium ausgesetzten Osteoblasten  
(Kontrolle Gruppe) (p = 0,02) (Abb. 2) 
Zusätzlich wurde der Einfluss von Strontium auf die Biomineralisation von 
konfluenten Runx2 +/- Osteoblasten in Gegenwart oder Abwesenheit von 3 mM 
Sr2+ untersucht. Die Färbung von extrazellulärer Matrix mit Alizarin Red-S zeigte 
eine statistisch signifikante Verbesserung der Mineralisierung von Strontium 
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inkubierten Runx2+/- Osteoblasten im Vergleich zur Gruppe der unbehandelten 
Osteoblasten (Abb.3). 
Runx2 hat eine entscheidende Rolle in der Differenzierung und der Funktion der 
Osteoblasten und damit im Knochenstoffwechsel (31). Weil Sr2+ eine stimulierende 
Wirkung auf die Differenzierung der Osteoblasten und die Reifung hat, wurde die 
Wirkung von Strontium auf die Proliferation der Runx2 +/- Osteoblasten getestet. 
Die Zunahme der Zellzahl entspricht der Konversion von WST-1 zu Formazan, die 
nachweisbar bei 450nm ist. Das 1,3 fach beschleunigte Wachstum von Runx2+/- 
Osteoblasten in Gegenwart von 3 mM Sr2 + ab dem 1. Tag bis zum 3. Tag zeigte 
aktivierende Wirkung von Strontium auf die Zellproliferation von Runx2+/- 
Osteoblasten (Abb. 4). 
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Abb. 3. Biomineralisation Effekt von 
Strontium auf die Runx2 +/- Osteoblasten 
Abb. 4. Wirkung von Strontium auf die 
Proliferation der Osteoblasten 
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10.4. Diskussion  
Aufgrund der aus der wissenschaftlichen Literatur bekannten positiven Wirkung 
von Strontium auf die Knochenbildung entwickelte sich die Überlegung, den 
Einfluss von Strontium auf Runx2+/- Osteoblasten zu untersuchen. Hierfür wurden 
Osteoblasten von einem Patienten mit dem Dysostosis cleidocranialis Syndrom 
entnommen. 
In dieser Studie verwendeten wir Strontiumchlorid (SrCl2) anstelle von 
Strontiumranelat, aufgrund der guten Löslichkeit des Salzes im verwendeten 
Zellmedium und der analogen Wirkung, die bereits in in vitro und in vivo-Studien 
gezeigt werden konnte (41, 42).  
Bei dieser Untersuchung wurde die Genexpression von zwei charakteristischen 
Osteoblasten-Genen, einerseits die alkalische Phosphatase und andererseits das 
Osteocalcin, überprüft.  
Beide Genprodukte sind im Knochengewebe an der Bildung und Mineralisierung 
beteiligt. ALP ist essentiell für die Mineralisierung des Knochens durch Hydrolyse 
von Pyrophosphat (43), während Osteocalcin vermutlich eine Rolle bei der 
Keimbildung von Hydroxylapatit-Kristallen spielt. (44) 
In dieser Studie wurde zwar eine  schwache, aber zumindest eine statistisch 
signifikant verbesserte Transkription der Gene ALP und OCN demonstriert. Dieses 
Ergebnis wurde durch die Alizarin Rot S Färbung positiv bestätigt, das als Hinweis 
interpretiert werden kann, dass Strontium die Mineralisierung der extrazellulären 
Matrix von Runx2+/--Osteoblasten verbessert. 
Die Enzymaktivität der ALP in  strontiumbehandelten Runx2+/- Osteoblasten  war 
signifikant höher als die ALP- Aktivität in unbehandelten Zellen.  
Ähnliche Ergebnisse von verbesserter Mineralisierung der extrazellulären Matrix 
und ALP-Aktivität wurden bei strontiumbehandelten mesenchymalen Zellen oder 
in Osteoblastvorläuferzellen beobachtet. 
Die Ergebnisse dieser ersten Pilotstudie lassen den Schluss zu, dass Strontium zu 
einer Aktivierung der transkriptionellen Aktivität der Gene für alkalische 
Phosphatase und Osteocalcin in Runx2+/--Osteoblasten führt, die allerdings im 
Vergleich zu normalen Osteoblasten sehr schwach ist. Es wird deshalb vermutet, 
dass die Verbesserung der Biomineralisierungsleistung der Runx2+/--Osteoblasten 
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vielmehr darauf zurückzuführen ist, dass die Zellproliferation bzw. das Wachstum 
der Zellen durch Strontium aktiviert wird. Weiterführende Untersuchungen an 
geeigneten Tiermodellen, wie z.B. Runx2+/--Mäusen sind notwendig, um 
nachzuweisen, ob die Verabreichung von Strontium an juvenilen Tieren tatsächlich 
zu einer Verringerung der Symptome von DCC (z. B. verzögerter Suturenschluss, 
nicht angelegte Schlüsselbeine, etc.) führt. 
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